Incremental Clinical Value of Single-Molecule Nanopore Sequencing in Thalassemia Testing: A Prospective Double-blind, Multicenter Study
Xiang, J.; Zhu, B.; Xu, H.; Chen, Y.; Sun, X.; xiang, r.; Zhao, Y.; Liu, W.; Zhang, L.; He, J.; liu, j.; Chen, Y.; Fan, Z.; Zhang, H.; Tan, J.; Pang, L.; Shi, L.; Kong, Y.; Cai, A.
Show abstract
Background Thalassemia is one of the most common monogenic disorders worldwide, current screening strategies combining hematological testing with molecular assays still carry a risk of missed diagnoses and undesirable efficiency, particularly for complex structural variants and rare mutations. Methods In this prospective double-blind, multicenter cohort study of 3,842 participants (3,362 pregnant women and 480 male partners), we conducted a head-to-head comparison to systematically evaluate the incremental clinical value and detection performance of single-molecule nanopore sequencing in thalassemia (SMITH) against conventional hematological testing and next-generation sequencing (NGS). Findings The overall concordance rate between NGS and SMITH was 98.6% (3789/3842). The discrepant cases (n=53) were directly attributed to the superior detection capabilities of SMITH, which successfully identified complex structural rearrangements-including 45 -globin gene triplications and four HK alleles-that were missed by NGS. Furthermore, SMITH accurately detected four rare variants (c.134_135insT/, c.-22(C>T)/, {beta}N/{beta}c.316-290delinsAGGGCAATAATTT and {beta}3.5 kb deletion/{beta}N ) and resolved ten trans and three cis configurations within the globin gene allele. Clinically, these technical advantages translated to a 9.3% (5/54) increase in the detection rate of high-risk prenatal couples, effectively preventing one birth affected by moderate-to-severe thalassemia. Additionally, SMITH corrected a diagnostic discrepancy in one case (HK vs. -3.7), sparing the couple from an unnecessary invasive procedure. Interpretation Our findings demonstrate that SMITH provides a powerful platform for resolving globin gene rearrangements, detecting rare variants, and enabling direct haplotype phasing. By effectively eliminating diagnostic blind spots, SMITH is expected to become an optimal method for thalassemia prevention programs. Funding This study was supported by Chinese National Natural Science Foundation Projects 81760037 and 82271894.
Matching journals
The top 2 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Whole genome sequencing association analysis of quantitative red blood cell phenotypes: the NHLBI TOPMed program 92%
- Returning Actionable Genomic Results in a Research Biobank: Analytic Validity, Clinical Implementation and Resource Utilization 91%
- Clinical validation of RNA sequencing for Mendelian disorder diagnostics 91%
Similar papers in this journal
- Validation of a Non-invasive Prenatal Test for Fetal RhD, C, c, E, Kell and FyA Antigens 93%
- A novel high-throughput molecular counting method with single base-pair resolution enables accurate single-gene NIPT 92%
- Rapid detection of G6PD deficiency SNPs using a novel amplicon-based MinION Sequencing Assay 90%
Similar papers in this journal
- Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients, as a function of therapeutic transfusion and hydroxyurea treatment 89%
- Variation and impact of polygenic hematological traits in monogenic sickle cell disease 88%
- Increased Frequency of Clonal Hematopoiesis of Indeterminate Potential in Bloom Syndrome Probands and Carriers 86%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.